Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia

The negative regulator of p53, MDM2, is frequently overexpressed in acute myeloid leukemia (AML) that retains wild-type TP53 alleles. Targeting of p53-MDM2 interaction to reactivate p53 function is therefore an attractive therapeutic approach for AML. Here we show that an orally active inhibitor of...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Nat Commun
Egile Nagusiak: Hayashi, Yasutaka, Goyama, Susumu, Liu, XiaoXiao, Tamura, Moe, Asada, Shuhei, Tanaka, Yosuke, Fukuyama, Tomofusa, Wunderlich, Mark, O’Brien, Eric, Mizukawa, Benjamin, Yamazaki, Satoshi, Matsumoto, Akiko, Yamasaki, Satoshi, Shibata, Tatsuhiro, Matsuda, Koichi, Sashida, Goro, Takizawa, Hitoshi, Kitamura, Toshio
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group UK 2019
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6814808/
https://ncbi.nlm.nih.gov/pubmed/31653912
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-019-12555-1
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak